



# Pervasive transcription enhances the accessibility of H-NS–silenced promoters and generates bistability in *Salmonella* virulence gene expression

Nara Figueroa-Bossi, María Antonia Sánchez-Romero, Patricia Kerboriou, Delphine Naquin, Clara Mendes, Philippe Bouloc, Josep Casadesús, Lionello Bossi

## ► To cite this version:

Nara Figueroa-Bossi, María Antonia Sánchez-Romero, Patricia Kerboriou, Delphine Naquin, Clara Mendes, et al.. Pervasive transcription enhances the accessibility of H-NS–silenced promoters and generates bistability in *Salmonella* virulence gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, pp.e2203011119. 10.1073/pnas.2203011119 . hal-03826124

HAL Id: hal-03826124

<https://hal.science/hal-03826124>

Submitted on 14 Nov 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Pervasive transcription enhances the accessibility of H-NS-silenced promoters  
and generates bistability in *Salmonella* virulence gene expression**

Nara Figueroa-Bossi<sup>a</sup>, María Antonia Sanchez-Romero<sup>b</sup>, Patricia Kerboriou<sup>a</sup>, Delphine Naquin<sup>a</sup>, Clara Mendes<sup>a</sup>, Philippe Bouloc<sup>a</sup>, Josep Casadesús<sup>c</sup> and Lionello Bossi<sup>a1</sup>

<sup>a</sup>Université Paris-Saclay, CEA, CNRS, Institut de Biologie Intégrative de la Cellule (I2BC), Gif-sur-Yvette, France, <sup>b</sup>Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain and <sup>c</sup>Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain

<sup>1</sup>To whom correspondence may be addressed. Email: lionello.bossi@i2bc.paris-saclay.fr

## **Abstract**

In *Escherichia coli* and *Salmonella*, many genes silenced by the nucleoid structuring protein H-NS are activated upon inhibiting Rho-dependent transcription termination. This response is poorly understood and difficult to reconcile with the view that H-NS acts mainly by blocking transcription initiation. Here we have analysed the basis for the upregulation of H-NS-silenced *Salmonella* Pathogenicity Island 1 (SPI-1) in cells depleted of Rho-cofactor NusG. Evidence from genetic experiments, semi-quantitative 5' RACE-Seq and ChIP-Seq shows that transcription originating from spurious antisense promoters, when not stopped by Rho, elongates into a H-NS-bound regulatory region of SPI-1, displacing H-NS and rendering the DNA accessible to the master regulator HilD. In turn, HilD's ability to activate its own transcription triggers a positive feedback loop that results in transcriptional activation of the entire SPI-1. Significantly, single-cell analyses revealed that this mechanism is largely responsible for the coexistence of two subpopulations of cells that either express or don't express SPI-1 genes. We propose that cell-to-cell differences produced by stochastic spurious transcription, combined with feedback loops that perpetuate the activated state, can generate bimodal gene expression patterns in bacterial populations.

Keywords: *Pervasive transcription, H-NS, Silencing, Pathogenicity Islands, Bistability*

### **Significance statement**

In bacteria, a large fraction of transcriptional noise originates from promoter-like sequences found in both orientations within coding sequences. This work shows that transcription from spurious promoters can modulate the gene silencing activity of H-NS, a bacterial chromatin protein that oligomerizes along the DNA forming filaments and bridged structures. Upon invading a patch of oligomerized H-NS, elongating transcription complexes “unzip” the nucleoprotein filament making the DNA accessible for binding by regulatory proteins and RNA polymerase. In *Salmonella*, this mechanism triggers a positive feedback loop that activates the virulence regulatory program. The occurrence of two subpopulations of cells that, although genetically identical, either express or don’t express virulence genes suggests that stochastic spurious transcription plays a role in the generation of bistability in bacteria.

## Introduction

Transcriptomic analyses of *E. coli* bacteria exposed to an inhibitor of transcription termination factor Rho have led to the recognition that a major activity of Rho and its cofactor NusG in growing cells is devoted to genome-wide suppression of ubiquitous antisense transcription genome-wide (1, 2). Thus, indirectly, these findings are also pertinent to transcription initiation, as they unveil the existence of a high-level spurious transcriptional noise apparently curbed by the termination activity of Rho. This notion gained momentum with the demonstration that *E. coli* genes contain a multitude of intragenic promoters in both sense and antisense orientations (3-5). The phenomenon is particularly dramatic in genomic regions thought to originate from horizontal transfer whose typically higher Adenine and Thymine (AT) content matches the sequence composition of the average bacterial promoter (6). The disproportionately high number of promoter-like sequences in AT-rich DNA can actually be a source of toxicity by causing RNA polymerase titration (7). The above studies have an additional common denominator: they implicate the nucleoid structuring protein H-NS. On the one hand, the sites of intragenic Rho-dependent termination colocalized with the regions bound by H-NS (1); on the other hand, H-NS was shown to play the major role of silencing the spurious intragenic promoters (5). These findings renewed the interest in understanding the hidden complexity of H-NS-RNA polymerase interactions (8).

A small abundant protein, H-NS oligomerizes along the DNA upon binding to high affinity AT-rich nucleation sites and spreading cooperatively to adjacent sequences through lower affinity interactions (9-11). The oligomerization process generates a higher-order superhelical structure thought to contribute to DNA condensation (12). The resulting nucleoprotein filaments effectively coat the DNA and thereby hamper promoter recognition by RNA polymerase (13). In addition, H-NS can repress transcription through the formation of bridged or looped DNA structures that trap RNA polymerase in the open complex (14, 15) or act as roadblocks against transcript elongation (16, 17). In particular, bridged but not linear H-NS filaments have been shown to promote Rho-dependent transcription termination by increasing transcriptional pausing in vitro (17). H-NS has gained considerable attention since the discovery of its role as a xenogeneic silencer. Due to its affinity for AT-rich DNA, H-NS preferentially binds to, and prevents the expression of sequences acquired through horizontal transfer (18, 19). In doing so, H-NS protects the bacterium against the toxicity of foreign DNA (7, 20, 21) and allows the evolution of mechanisms for co-opting newly acquired functions and regulating their expression (22, 23). Indeed, the vast majority of H-NS-silenced genes are tightly regulated and expressed only under a limited set of conditions. Activation of H-NS-silenced genes typically results from the binding or the action of regulators able to displace H-NS (24-26). Unlike classical gene activation, H-NS counter-silencing exhibits considerable flexibility in the spatial arrangement of the regulator protein relative to the promoter (27).

In *Salmonella enterica*, H-NS silences most of the genes that contribute to virulence, including *Salmonella* Pathogenicity Islands (SPIs) that are specifically activated in the environment of the infected host (18, 19). SPI activation occurs in the form of a hierarchical and temporal regulatory cascade that begins with the expression of SPI-1, a 44 Kb-island encoding a Type III Secretion System (T3SS) that delivers effector proteins promoting intestinal colonization and epithelial cell invasion (28, 29). Several lines of evidence suggest that the process is initiated by HilD, a SPI-1-encoded AraC-type transcriptional regulator that activates the expression of a second master regulator, HilA, which in turns activates the T3SS along with the product of a third regulatory gene, *invF* (30). Acting as a hub integrating diverse environmental and physiological signals, HilD is itself regulated at multiple levels including mRNA stability (31) mRNA translation (32, 33) and protein activity (33, 34). However, central to the regulatory cascade is the ability of HilD to activate its own synthesis. HilD binds to an extended region upstream of the *hilD* promoter in vitro (35) and in vivo (36). The presence of this region among the DNA fragments bound by H-NS in chromatin immunoprecipitation (ChIP) experiments suggests that HilD stimulates transcription of its own gene by antagonizing H-NS (37). Interestingly, SPI-1 exhibits a bistable expression pattern characterized by the presence of two subpopulations of cells that either express or don't express SPI-1 genes (38-43). In laboratory cultures, the SPI-1<sup>OFF</sup> population vastly predominates; however, SPI-1<sup>ON</sup> cells are continuously produced and persist for several generations (42, 44) despite the fitness cost associated with the synthesis and assembly of the T3SS, which results in growth retardation (45). Retarded growth, however, makes the SPI-1<sup>ON</sup> subpopulation tolerant to antibiotics (46). SPI-1<sup>OFF</sup> cells also benefit from bistability: inflammation triggered by the T3SS of SPI-1<sup>ON</sup> cells leads to the production of reactive oxygen species in phagocytes. Such chemicals produce tetrathionate upon oxidation of endogenous sulphur compounds, and tetrathionate respiration confers a growth advantage to *Salmonella* over competing species of the intestinal microbiota (47). Furthermore, SPI-1<sup>OFF</sup> cells can invade the intestinal epithelium, a capacity that may benefit the population as a whole by countering invasion by avirulent mutants (38, 39, 42).

We recently found that inhibiting Rho-dependent transcription termination, by mutation or through the depletion of Rho cofactor NusG, causes massive upregulation of many *Salmonella* virulence genes including all major SPIs (16). The magnitude and the span of these effects suggested that they were not produced locally but reflected the activation of a global regulatory response. This led us to turn our attention to HilD. The work described below confirmed the HilD involvement and provided new insight on the interplay between transcription elongation and bacterial chromatin. In particular, our data suggest that H-NS-bound regions are not completely impermeable to RNA polymerase. Occasional spurious transcription initiation events within these regions trigger a relay cascade whereby elongating transcription complexes, if not stopped by Rho, dislodge H-NS oligomers making more promoters accessible to RNA polymerase and regulatory proteins. In addition, these findings support a model for the mechanism underlying SPI-1 bistability.

## Results

**Most of the *Salmonella* response to NusG depletion is HilD-mediated.** In all analyses described below, NusG depletion is achieved in strains with the sole copy of the *nusG* gene fused to a phage promoter under the control of an arabinose-inducible repressor (16). In the presence of arabinose (ARA), activation of the repressor gene causes the *nusG* gene to be turned off and its product to be progressively depleted. Although NusG is essential for *Salmonella* viability (48), the treatment is not lethal since residual NusG synthesis is sufficient to support growth. In fact, growth is nearly unaffected by ARA until bacteria enter early stationary phase. At this point the growth rate becomes significantly reduced, apparently as a side effect of the strong activation of SPIs (45).

To assess the possible role of HilD in the response to NusG depletion, we measured the expression of *lacZ* translational fusions to three SPI genes: *invB* (SPI-1) *sseE* (SPI-2) and *sopB* (SPI-5) in a *hilD*<sup>+</sup> strain and in a strain in which the *hilD* gene is replaced by a *tetRA* cassette. ARA exposure elicited a sharp increase in the expression of all three fusions in both *hilD*<sup>+</sup> and *hilD*<sup>-</sup> backgrounds; however, the changes in the *hilD*<sup>+</sup> strain occurred within a range between 10- to 50-fold higher than in the  $\Delta hilD::tetRA$  mutant (*SI Appendix*, Fig. S1), pointing to the HilD involvement in the ARA-mediated activation of SPIs. To examine this response at the single cell level, we constructed in-frame fusions of superfolder green fluorescent protein (GFP<sup>SF</sup>) to HilD-regulated genes. Two fusions, in *hilA* and *invB*, were obtained by inserting the *gfp*<sup>SF</sup> open reading frame (orf) in the target gene; a third fusion, also in *hilA*, was made by concomitantly deleting a 28,266 bp segment spanning nearly the entire SPI-1 portion on the 3' side of the fusion boundary. As initial experiments showed no significant differences in the behaviors of the three strains, only the strain with the 28 Kb SPI-1 deletion (*hilA::gfp*<sup>SF</sup> $\Delta K28$ ) was used for subsequent analyses.

**NusG depletion promotes SPI-1 bistability.** Cells carrying *hilA::gfp*<sup>SF</sup> $\Delta K28$  display a typical bistable phenotype characterised by the presence of two subpopulations of bacterial cells, of which only one subpopulation shows GFP fluorescence (Fig. 1A). Significantly, growth in the presence of ARA causes the ratio between *hilA*<sup>ON</sup> and *hilA*<sup>OFF</sup> cells to increase dramatically in early stationary phase (Fig. 1A). Flow cytometric measurements show the increase to be more than 10-fold (Fig. 1B, *SI Appendix*, Fig. S2). SPI-1 bistability has been linked to the self-activating nature of *hilD* expression and it is thought to reflect cell-to-cell variability in HilD levels (32, 33, 41). In line with this model, *hilA*<sup>ON</sup> cells are no longer detected in a strain carrying a 309 bp in-frame deletion removing the DNA binding motif in the carboxyl-terminal domain of HilD (Fig. 1C, *SI Appendix* Fig. S2). These results suggest that NusG depletion allows a larger fraction of cells to reach the HilD autoactivation threshold. Consistent with this conclusion, RNA quantification by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) shows that the ARA treatment causes a large increase in *hilD* transcription when HilD is functional but a smaller increase in the *hilD* $\Delta 309$  mutant (Fig. 2A). The analysis reveals that HilD is also needed for the expression of the adjacent *prgH* gene (Fig. 2B). At first sight, this

may seem surprising since *prgH* is thought to be activated by HilA, not by HilD (37, 49) and the strain used in Fig. 2B carries the *hilA::gfp<sup>SF</sup>* $\Delta$ K28 allele which removes over two thirds of the *hilA* sequence. However, we note that the fusion retains the N-terminal 112 amino acids (aa) domain of HilA previously implicated in *prgH* promoter recognition (50) suggesting that the HilA-GFP chimera retains the ability to activate *prgH*.

**Pervasive transcription activates the *hilD* promoter.** The central role of HilD in the response to NusG depletion was further corroborated by the observation that ARA treatment stimulates HilD binding to the *hilD* promoter region (Fig. 2C), a response that correlates with the activation of the *hilD* and *prgH* promoters (Fig. 2D and E). This last set of data were obtained performing semi-quantitative 5' rapid amplification of cDNA ends (5' RACE) generated by template switching reverse transcription (TS RT) (51). In this method, reverse transcription is primed by a gene-specific primer and carried out in the presence of a template switching oligonucleotide (TSO). The 5' ends of RNAs are defined by the position the cytidine repeats (typically 3 or 4) that are added by reverse transcriptase when it reaches the end of the RNA and switches to the TSO (51). Use of primers carrying Illumina adaptors for the PCR step allows for the analysis to be performed by high throughput sequencing (RACE-Seq). Here, primers were designed to detect transcription initiation taking place at the primary *hilD* and *prgH* promoters as well as at three secondary promoters previously identified by Kröger and coworkers (52) (*SI Appendix*, Fig. S3). Read summarization at each of the transcription start sites (TSSs) showed that ARA exposure causes the number of transcripts initiating at *hilD* and *prgH* primary TSSs to increase 7-fold and 13-fold, respectively (Fig. 2D and E). The most likely explanation of this effect is that NusG depletion allows transcription complexes formed outside the *prgH-hilD* promoter region to invade this region displacing H-NS and triggering HilD autogenous activation. Prime suspects for this effect are the secondary *hilD* promoters whose activity contributes to the *hilD* mRNA increase (*SI Appendix*, Fig. S4A). However, the experiment does not distinguish whether the increase in the number of reads associated with the secondary TSSs is due to a larger proportion of transcripts reaching the RT primer site (and thus susceptible to reverse transcription) in ARA treated cells or reflect an increase in promoter activity. If the latter were true, the implication would be that the secondary promoters are themselves activated by transcription initiating elsewhere, presumably further upstream, and they relay the effect to the *hilD* promoter. To address this point, we performed parallel qPCR measurements using primers pairs annealing at proximal and distal positions relative to the RT priming site. Results showed that a significant fraction of transcripts entering the *hilD* coding sequence in ARA-treated cells initiate as far as over 1400 bp upstream from the *hilD* promoter (compare red bars between PCR-1 and PCR-2 in Fig. 2F), thus considerably upstream relative to the secondary promoters. It is therefore conceivable that the elongation of these overlapping transcripts may activate the secondary promoters. Interestingly, this class of transcripts is also detectable in untreated cells (green bars in Fig. 2F) albeit at very low level. A similar trend is observed in the opposite strand where a fraction of *prgH* RNAs originates from anti-sense *hilD* transcription (Fig. 2G).

To further assess the contribution of upstream transcription to *hilD* promoter activity, the SPI-1 segment extending from the left boundary of the island up to a position 610 bp upstream of the *hilD* main TSS was deleted and replaced by a cassette comprising the *tetR* gene and the TetR-repressed  $P^{tetA}$  promoter (Fig. 3A). The transcriptional responses to ARA and to the  $P^{tetA}$  inducer, Anhydrotetracycline (AHTc), alone or combined, were analyzed by RT-qPCR and 5'RACE Seq. ARA was still able to activate transcription of *hilD* and *prgH* in the new background (Fig. 3B and C); however, activation was more moderate than seen above with the parental strain (compare to Fig. 2A and B, respectively); furthermore, no significant changes were observed at the level of the *hilD* and *prgH* primary TSSs (Fig. 3D and E). These findings corroborate the idea that the region deleted in the new construct contributes to the amplitude of the ARA effects. Activating  $P^{tetA}$  with AHTc stimulates *hilD* and *prgH* transcription (Fig. 3B and C); here too, however, the effect remains limited and undetectable by 5'RACE-Seq at the primary TSSs (Fig. 3D and E). In contrast, when AHTc and ARA are used conjointly, transcription of both *hilD* and *prgH* genes is strongly activated (Fig. 3B and C) and an initiation burst is observed at the level of both primary promoters (Fig. 3D and E). Significantly, this burst correlates with increased occupancy of the *hilD* promoter by the HilD protein (Fig. 3F). The secondary promoters exhibit a similar overall response, which is however characterized by pronounced scatter in the individual Ara/AHTc treatments (*SI Appendix*, Fig. S4B). The overall strength of the *hilD* response can be correlated with the detection of higher levels of  $P^{tetA}$  transcription in the presence of ARA (*SI Appendix*, Fig. S4C).

In the background of the *hilA-gfp<sup>SF</sup>* fusion (which deletes the right two thirds of SPI -1), the deletion generated by the *tetR-P<sup>tetA</sup>* insertion constitutes a minimal system with only two SPI-1 genes, *hilD* and *pphB*, remaining intact. Significantly, this strain still exhibits the HilD-dependent bistable phenotype, suggesting that HilD is not only required but also sufficient for bistability (Fig. 4A and B). Growth in a medium supplemented with AHTc affects the basal *hilA<sup>ON</sup>/hilA<sup>OFF</sup>* ratio only marginally unless ARA is also present, in which case the vast majority of the cell population switches to the *hilA<sup>ON</sup>* status (Fig. 4A and B, *SI Appendix*, Fig. S5). To confirm that the ARA effects depend on transcription originating upstream of *hilD*, and not by an alternative, unidentified mechanism stimulating *hilD* expression when NusG is depleted, we constructed a strain carrying the strong Rho-independent transcription terminator from the histidine operon attenuator region (Term<sup>hisL</sup>) immediately downstream from  $P^{tetA}$  in the *hilA::gfp<sup>SF</sup>ΔK28* background (*SI Appendix*, Fig. S6A and B). During construction, a clone displaying strong green fluorescence on a plate supplemented with ARA and AHTc was identified. Sequence analysis revealed that this isolate harbors a deletion removing 6 out of the 9 repeated Us at the 3' end of Term<sup>hisL</sup>. Both the strain with the wild-type Term<sup>hisL</sup> insert and the Δ6U derivative were used for bistability assays. Results showed that Term<sup>hisL</sup> abolishes all effects of ARA on *hilA* OFF/ON ratios both in the absence and in the presence of AHTc (*SI Appendix*, Fig. S6C and E). Interestingly, the Δ6U deletion reverses this pattern causing about half of the cell population to switch to the *hilA* ON status in the presence of ARA alone and virtually the entire population to switch ON in the presence of ARA and AHTc combined. (*SI Appendix*, Fig. S6D and F). These results provide conclusive evidence that transcription

originating more than 600 bp upstream of *hilD*'s primary TSS is solely responsible for the effects of NusG depletion on *hilD* expression. Since *hilD* secondary promoters are all located downstream from Term<sup>hisL</sup>, these data also support the idea that they play no direct role in the ARA-induced activation of the primary promoter.

**Viewing SPI-1 upregulation at the chromatin level.** In parallel with the above studies, we sought to determine whether NusG depletion affected the binding of H-NS to SPI-1 and other genomic islands. For this purpose, chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-Seq) was performed in strains carrying the NusG-repressible allele and an epitope tagged version of H-NS. Examination of the ChIP-Seq profiles in the SPI-1 section of the genome showed a succession of peaks and valleys consistent with the presence of multiple contiguous patches of oligomerized H-NS separated by segments with little or no H-NS bound (Fig. 5A). Superimposing the profiles from cells growing in the absence or in the presence of ARA reveals small but nonetheless appreciable differences in the levels of DNA fragments bound by H-NS. One can see that a number of peaks shrink as a result of the ARA treatment (Fig. 5A). Interestingly, the most conspicuous changes are detected in the *hilD-hilA* ad *invF-invH* sections of SPI-1, corresponding to the locations of main regulatory hubs (30). In contrast, no changes are observed at the far-right end of SPI-1 (*pigA-pphB* segment (53)) and in the central portion of the island. Read depth quantification confirmed the profile changes. ARA treatment lowers H-NS binding in the *hilD-hilA* and *invF-invH* intervals by 34% and 47%, respectively, while having no effect in the *pigA-pphB* region (Fig. 5B). Likewise, no appreciable differences are observed at the *proV* locus (54) (Fig. 5B). ChIP-Seq analysis was also performed in the strain carrying the *tetR-P<sup>tetA</sup>-* and *hilA::gfp<sup>SF</sup>*ΔK28-associated deletions, comparing unchallenged cells to cells grown in the presence of both ARA and AHTc (Fig. 5C). Somewhat surprisingly, the double treatment caused only a 20% reduction of H-NS binding in the *hilD-hilA* interval (Fig. 5D). In both above analyses, visual inspection of the profiles around other H-NS-bound loci known to be upregulated in NusG-depleted cells (16) failed to reveal appreciable differences. Finding that transcriptional changes produce comparatively small or undetectable alterations in H-NS binding is not novel (24, 26) and suggests that H-NS-DNA complexes exist dynamically and rapidly reform after the passage of transcription elongation complexes.

## Discussion

This study was aimed at understanding why impairing Rho-dependent transcription termination by depletion of Rho-cofactor NusG relieves H-NS silencing of *Salmonella* pathogenicity islands. We show that NusG depletion triggers a positive feedback loop that generates and maintains HilD, the master regulator of the *Salmonella* virulence regulatory cascade. Accumulation of HilD is primarily responsible for H-NS counter-silencing in NusG-depleted cells. This is directly demonstrated for SPI-1, SPI-2 and SPI-5 genes, but it seems likely that the HilD involvement may extend to most, if not all, islands and islets upregulated in NusG-depleted cells (16). Note that although SPI-1 and SPI-2 are generally activated in

response to sharply different cues, HilD-mediated crosstalk allows expression of SPI-2 genes under conditions unusual for this island, notably in rich medium (55, 56).

By oligomerizing along the DNA, H-NS silences not only *bona fide* promoters at the 5' end of genes but also a plethora of spurious intragenic promoters that "infest" A/T-rich horizontally acquired DNA (5-7). Finding that the inhibition of Rho or NusG causes widespread sense and antisense transcription of H-NS-silenced genes (1, 16) suggests that H-NS-bound DNA is susceptible to transcriptional invasion and that Rho (recruited by NusG) acts to prevent elongation of invading transcription complexes. Various lines of evidence suggest that H-NS-bound regions are not totally impermeable to RNA polymerase. Existence of several very short transcripts initiating from within H-NS-associated loci was previously inferred from a genome-wide analysis of TSSs in *E. coli* (4). More recently, parallel ChIP-Seq TSS mapping experiments showed a clear TSS being used upstream of the *E. coli ydbCD* operon, even when H-NS was present, but no full-length mRNA (6). Finally, in our previous work, we found that a *tetR-P<sup>tetA</sup>* cassette placed only 57 bp away from the H-NS nucleation site in the *leuO* promoter region of *Salmonella* normally responds to AHTc induction (although leading to LeuO synthesis only when NusG is depleted) (16). Elongating through a patch of oligomerized H-NS, RNA polymerase can dislodge H-NS and allow other RNA polymerase molecules to gain access to normally silenced promoters thus further contributing to transcriptional noise (57, 58). The data presented here show that transcriptional "noise" can be converted into a true regulatory "melody" if the activated promoter directs the synthesis of a positive autoregulator. In the model schematized in Fig. 6, we posit that a transcription complex formed at a spurious promoter ("Px"), if not stopped by Rho, "unzips" the H-NS nucleoprotein filament in the *hilD* promoter region, triggering a positive feedback loop that results in HilD accumulation and concomitant derepression of both *hilD* and *prgH*. Antisense transcription from inside *hilD* (not shown for simplicity in Fig. 6) may contribute to destabilization of the H-NS-DNA complex. Note that transcription may not need to travel all the way to the promoter sequence in order to cause H-NS dissociation. Due to the multi-contact nature of the H-NS-DNA interaction (54), disruption of contacts at the edge of the oligomerization patch could be sufficient to destabilize the entire patch. By linking *hilD* activation to a stochastic and likely infrequent transcription event – *i.e.*, initiation at a spurious promoter or readthrough of a Rho-dependent terminator by a spurious transcript – the model can explain the bistability in the expression of HilD-regulated loci and suggests that the frequency of these events may set SPI-1 ON/OFF subpopulation ratios during normal growth. The HilD/H-NS interplay in the regulation of SPI-1 bears analogy with the mechanism regulating the expression of the Locus of Enterocytes Effacement (LEE) of enteropathogenic *Escherichia coli*. Here too, expression is characterized by a bistable response (59), suggesting that the interplay between H-NS and regulatory proteins (Ler in this case) may constitute an elemental premise for bistability. Whether LEE regulation responds to pervasive transcription is currently unknown.

Eukaryotic genomes, including the predominant non-coding fraction of human genomes, are pervasively transcribed and this process strongly impacts gene regulation and chromatin structure (60, 61). In prokaryotes, various potential roles of pervasive antisense

transcription in gene regulation and genome evolution were considered (62) but, to date, such roles have remained hypothetical. Data presented here show that the elongation of pervasive transcripts into H-NS-DNA complexes can act as a counter-silencing mechanism modulating a regulatory response. Although most of the effects were observed under conditions of impaired transcription termination, low-level readthrough transcripts were detected in unchallenged cells suggesting that their effects (*e.g.*, bistability) are exerted during normal growth. This study adds elongation of pervasive transcripts to the set of mechanisms that produce transcriptional noise (63) and provides a model to understand the molecular basis of SPI-1 bistability, which has remained a longstanding mystery in *Salmonella* biology. The model fits well in the view that stochastic cell-to-cell differences perpetuated by feedback loops can generate phenotypic lineages (64, 65).

## Materials and Methods

**Strains and culture conditions.** All strains used in this work are derived from *Salmonella enterica* serovar Typhimurium strain LT2 (66). Strains and their genotypes are listed in *SI Appendix*, Table S1. Bacteria were routinely cultured in Lysogeny Broth (LB: Tryptone 10 g/l, Yeast extract 5 g/l, NaCl, 5 g/l) at 37°C or, occasionally, at 30°C when carrying temperature-sensitive plasmid replicons. Typically, bacteria were grown overnight in static 2 ml cultures (14 mm diameter tubes), subcultured by 1:200 dilution the next day (20 ml culture in 125 ml Erlenmeyer flasks) and grown with 170 rpm shaking. For growth on plates, LB was solidified by the addition of 1.5% Difco agar. When needed, antibiotics (Sigma-Aldrich) were included in growth media at the following final concentrations: chloramphenicol, 10 µg/ml; kanamycin monosulphate, 50 µg/ml; sodium ampicillin 100 µg/ml; spectinomycin dihydrochloride, 80 µg/ml; tetracycline hydrochloride, 25 µg/ml. Strains were constructed by generalized transduction using the high-frequency transducing mutant of phage P22, HT 105/1 *int*-201 (67) or by the  $\lambda$ -*red* recombineering technique implemented previously (68). 3xFLAG epitope fusions were constructed as described (69) or by two-step scarless recombineering. The latter procedure involved the use of tripartite selectable counter-selectable cassettes (conditionally expressing the *ccdB* toxin gene) amplified from in-house-developed plasmid templates. Oligonucleotide used as primers for amplification (obtained from Sigma-Aldrich or Eurofins) are listed in *SI Appendix*, Table S2. Their assortment for the construction of the relevant alleles used in this study is shown in *SI Appendix*, Table S3. PCR-amplified fragments to be used for recombineering were produced with high-fidelity Phusion polymerase (New England Biolabs). Constructs were verified by colony-PCR using Taq polymerase followed by DNA sequencing (performed by Eurofins-GATC Biotech).

**Fluorescence microscopy.** Bacterial cultures grown overnight in LB at 37°C were diluted 1:200 into 2 ml of the same medium with or without 0.1% arabinose and/or 0.4 µg/ml AHTc (in 14 mm diameter tubes) and grown for 4 hours at 37°C with shaking (170 rpm). Cells were then harvested by centrifugation (2 min at 12,000 x g), washed once in PBS and used immediately for microscopic examination. Images were captured with a Leica DM 6000 B microscope (CTR 6500 drive control unit) equipped with a EBQ 100 lamp power unit and filters for phase contrast, GFP and mCherry detection (100 x oil immersion objective). Pictures were taken with a Hamamatsu C11440 digital camera and processed with Metamorph software.

**Flow cytometry.** Flow cytometry was used to monitor expression of translational GFP fusions. Data acquisition was performed using a Cytomics FC500-MPL cytometer (Beckman Coulter, Brea, CA) and data were analyzed with FlowJo X version 10.0.7r software (Tree Star, Inc., Ashland, OR). *S. enterica* cultures were washed and re-suspended in phosphate-buffered saline (PBS) for fluorescence measurement. Fluorescence values for 100,000 events were compared with the data from the reporterless control strain, thus yielding the fraction of ON and OFF cells.

**RNA extraction and quantification by RT-qPCR.** Overnight bacterial cultures in LB were diluted 1:200 in the same medium – or in LB supplemented with 0.1% ARA or 0.4 µg/ml Anhydrotetracycline (AHTc) or both drugs where appropriate – and grown with shaking at 37°C to an OD<sub>600</sub> = 0.7 to 0.8. Cultures (4 ml) were rapidly spun down and resuspended in 0.6 ml ice-cold REB buffer (20 mM Sodium Acetate pH 5.0, 10% sucrose). RNA was purified by sequential extraction with hot acid phenol, phenol-chloroform 1:1 mixture and chloroform. Following overnight ethanol precipitation at -20°C and centrifugation, the RNA pellet was resuspended in 20 µl of H<sub>2</sub>O. Three samples were prepared from independent biological replicates for each strain and condition. RNA yields, measured by Nanodrop reading, typically ranged between 2 and 3 µg/µl. The RNA preparations were used for first-strand DNA synthesis with the New England Biolabs (NEB) ProtoScript II First Strand DNA synthesis kit, following the manufacturer's specifications. Briefly, RNA (1 µg) was combined with 2 µl of a mixture of two primers (5 µM each), one annealing in the promoter proximal portion of the RNA to be quantified (primer AI41 for *hilD* or primer AI48 for *prgH*), the other annealing to a similar position in the reference RNA (primer AJ33 for *ompA*) in an 8 µl final volume. After 5' min at 65°C and a quick cooling step on ice, volumes were brought to 20 µl by the addition of 10 µl of ProtoScript II Reaction Mix (2x) and 2 µl of ProtoScript II Enzyme Mix (10x). Mixes were incubated for one hour at 42°C followed by a 5 min enzyme inactivation step at 80°C. Samples were then used for real time quantitative PCR as described in *SI Appendix, Supplementary Materials and Methods*.

**5' RACE-Seq analysis.** RNA 5'-end analysis was carried out by template switching reverse transcription (51) coupled to PCR. Initially, we applied this technique on RNA pretreated with Vaccinia virus capping enzyme as reported previously (70). However, these initial tests indicated that the capping step is unnecessary; therefore, this step was subsequently omitted. From that point on, we followed the protocol described by the Template Switching RT Enzyme Mix provider (New England Biolabs) with a few modifications (*SI Appendix, Supplemental Materials and Methods*). The synthesized cDNA was amplified by PCR with primers carrying Illumina adapters at their 5' ends. Several PCRs were carried out in parallel with a common forward primer (AJ38, annealing to the TSO) and a reverse primer specific for the region being analysed and carrying a treatment-specific index sequence (see example in *SI Appendix*, Fig. S3). Reactions were set up according to New England Biolabs PCR protocol for Q5 Hot Start High-Fidelity DNA polymerase in a final volume of 50 µl (using 1 µl of the above cDNA preparation per reaction). The number of amplification cycles needed for reproducible semiquantitative measurements, determined in trial experiments, was chosen to be 25 for the *ompA* reference, 30 for the primary *hilD* and *prgH* promoters and 35 for the secondary *hilD* promoters and the P<sup>tetA</sup> promoter. The PCR program was as follows: activation: 98°C for 30 sec; amplification (25 or 30 or 35 cycles): 98°C for 10 sec; 65°C for 15 sec; 72°C for 30 sec; final stage: 72°C for 5 min. Products from parallel PCRs were mixed in equal volumes; mixes originating from the amplification of separate regions were pooled and the pools subjected to

high throughput sequencing. The procedure was implemented at least once, occasionally twice, with each of the independent RNA preparations. The counts of reads containing the TSO sequence positioned at the TSSs analysed here, each normalized to the counts of reads containing the TSO positioned at the *ompA* TSS, were used to calculate the ratios between the activity of a promoter under a given treatment relative and its activity in untreated cells. The raw data from RACE-Seq experiments were deposited into ArrayExpress under the accession number E-MTAB-11419.

**ChIP-Seq analysis.** Overnight bacterial cultures were diluted 1:100 in LB or in LB supplemented with 0.1% ARA or 0.1% ARA + 0.4 µg/ml AHTc and grown at 37°C to an OD600 of 0.7-0.8. At this point 1.6 ml of 37% Formaldehyde (Alfa Aesar) were added to 30 ml of culture and the culture incubated for 30 min at room temperature with gentle agitation. This was followed by the addition of 6.8 ml of a 2.5 M glycine solution and further 15 min incubation with gentle agitation at room temperature. Cells were centrifuged and the pellet resuspended in 24 ml of TBS buffer (50 mM Tris HCl pH7.4, 150mM NaCl). These steps were repeated once and the cells centrifuged again. Cells were then processed for ChIP as previously described (71) and adapted here to *Salmonella* (see *SI Appendix, Supplementary Materials and Methods*). The raw data from all ChIP-Seq experiments were deposited into ArrayExpress under the accession number E-MTAB-11386.

**Statistics, Reproducibility and Bioinformatic analyses.** See *SI Appendix, Supplementary Materials and Methods*.

### Acknowledgments

We are grateful to Vicky Lioy for advice on ChIP experiments and to Modesto Carballo, Laura Navarro and Cristina Reyes (Servicio de Biología, CITIUS, Universidad de Sevilla) for help with the flow cytometry analysis. We thank the High-throughput Sequencing Core Facility of the I2BC (Gif-sur-Yvette) for library preparation and sequencing (ChIP-Seq and RACE-Seq) and the ICGex NGS platform of the Curie Institute (Paris) for generating some of the sequence data sets (RACE-Seq). This study was supported by the Centre National de la Recherche Scientifique (CNRS), by the Agence Nationale de la Recherche (ANR-15-CE11-0024-03) France and by Grant BIO2016-75235-P (Ministerio de Ciencia e Innovación, Spain and the European Regional Fund). ChIP-Seq data and RACE-Seq data were deposited into ArrayExpress under the accession numbers E-MTAB-11386 and E-MTAB-11419, respectively.

### Author contributions

N.F.B., M.S.R, J.C. and L.B. designed research; N.F.B., M.S.R, P.K., C.M. and L.B. performed research; D.N. and P.B. contributed new reagents/analytical tools; N.F.B, M.S.R., D.N. and L.B. analyzed data; N.F.B., J.C. and L.B. wrote the paper.

## References

1. J. M. Peters *et al.*, Rho and NusG suppress pervasive antisense transcription in *Escherichia coli*. *Genes Dev* **26**, 2621-2633 (2012).
2. J. M. Peters *et al.*, Rho directs widespread termination of intragenic and stable RNA transcription. *Proc Natl Acad Sci U S A* **106**, 15406-15411 (2009).
3. L. Ettwiller, J. Buswell, E. Yigit, I. Schildkraut, A novel enrichment strategy reveals unprecedented number of novel transcription start sites at single base resolution in a model prokaryote and the gut microbiome. *BMC Genomics* **17**, 199 (2016).
4. V. V. Panyukov, O. N. Ozoline, Promoters of *Escherichia coli* versus promoter islands: function and structure comparison. *PLoS One* **8**, e62601 (2013).
5. S. S. Singh *et al.*, Widespread suppression of intragenic transcription initiation by H-NS. *Genes Dev* **28**, 214-219 (2014).
6. D. Forrest, E. A. Warman, A. M. Erkelens, R. T. Dame, D. C. Grainger, Xenogeneic silencing strategies in bacteria are dictated by RNA polymerase promiscuity. *Nat Commun* **13**, 1149 (2022).
7. L. E. Lamberte *et al.*, Horizontally acquired AT-rich genes in *Escherichia coli* cause toxicity by sequestering RNA polymerase. *Nat Microbiol* **2**, 16249 (2017).
8. R. Landick, J. T. Wade, D. C. Grainger, H-NS and RNA polymerase: a love-hate relationship? *Curr Opin Microbiol* **24**, 53-59 (2015).
9. C. J. Dorman, H-NS: a universal regulator for a dynamic genome. *Nat Rev Microbiol* **2**, 391-400 (2004).
10. C. J. Dorman, J. C. Hinton, A. Free, Domain organization and oligomerization among H-NS-like nucleoid-associated proteins in bacteria. *Trends Microbiol* **7**, 124-128 (1999).
11. F. C. Fang, S. Rimsky, New insights into transcriptional regulation by H-NS. *Curr Opin Microbiol* **11**, 113-120 (2008).
12. S. T. Arold, P. G. Leonard, G. N. Parkinson, J. E. Ladbury, H-NS forms a superhelical protein scaffold for DNA condensation. *Proc Natl Acad Sci U S A* **107**, 15728-15732 (2010).
13. C. Ueguchi, T. Mizuno, The *Escherichia coli* nucleoid protein H-NS functions directly as a transcriptional repressor. *Embo J* **12**, 1039-1046 (1993).
14. R. T. Dame, C. Wyman, R. Wurm, R. Wagner, N. Goosen, Structural basis for H-NS-mediated trapping of RNA polymerase in the open initiation complex at the rrnB P1. *J Biol Chem* **277**, 2146-2150 (2002).
15. M. Shin *et al.*, DNA looping-mediated repression by histone-like protein H-NS: specific requirement of Esigma70 as a cofactor for looping. *Genes Dev* **19**, 2388-2398 (2005).
16. L. Bossi *et al.*, NusG prevents transcriptional invasion of H-NS-silenced genes. *PLoS Genet* **15**, e1008425 (2019).
17. M. V. Kotlajich *et al.*, Bridged filaments of histone-like nucleoid structuring protein pause RNA polymerase and aid termination in bacteria. *Elife* **4** (2015).
18. S. Lucchini *et al.*, H-NS mediates the silencing of laterally acquired genes in bacteria. *PLoS Pathog* **2**, e81 (2006).
19. W. W. Navarre *et al.*, Selective silencing of foreign DNA with low GC content by the H-NS protein in *Salmonella*. *Science* **313**, 236-238 (2006).
20. S. S. Ali, B. Xia, J. Liu, W. W. Navarre, Silencing of foreign DNA in bacteria. *Curr Opin Microbiol* **15**, 175-181 (2012).
21. C. J. Dorman, H-NS, the genome sentinel. *Nat Rev Microbiol* **5**, 157-161 (2007).

22. S. S. Ali *et al.*, Silencing by H-NS potentiated the evolution of *Salmonella*. *PLoS Pathog* **10**, e1004500 (2014).
23. K. Higashi *et al.*, H-NS Facilitates Sequence Diversification of Horizontally Transferred DNAs during Their Integration in Host Chromosomes. *PLoS Genet* **12**, e1005796 (2016).
24. J. C. Perez, T. Latifi, E. A. Groisman, Overcoming H-NS-mediated transcriptional silencing of horizontally acquired genes by the PhoP and SlyA proteins in *Salmonella enterica*. *J Biol Chem* **283**, 10773-10783 (2008).
25. D. M. Stoebel, A. Free, C. J. Dorman, Anti-silencing: overcoming H-NS-mediated repression of transcription in Gram-negative enteric bacteria. *Microbiology (Reading, England)* **154**, 2533-2545 (2008).
26. W. R. Will, D. H. Bale, P. J. Reid, S. J. Libby, F. C. Fang, Evolutionary expansion of a regulatory network by counter-silencing. *Nat Commun* **5**, 5270 (2014).
27. W. R. Will, W. W. Navarre, F. C. Fang, Integrated circuits: how transcriptional silencing and counter-silencing facilitate bacterial evolution. *Curr Opin Microbiol* **23**, 8-13 (2015).
28. J. R. Ellermeier, J. M. Slauch, Adaptation to the host environment: regulation of the SPI1 type III secretion system in *Salmonella enterica* serovar Typhimurium. *Curr Opin Microbiol* **10**, 24-29 (2007).
29. J. E. Galán, *Salmonella* interactions with host cells: type III secretion at work. *Annual review of cell and developmental biology* **17**, 53-86 (2001).
30. C. D. Ellermeier, J. R. Ellermeier, J. M. Slauch, HilD, HilC and RtsA constitute a feed forward loop that controls expression of the SPI1 type three secretion system regulator hilA in *Salmonella enterica* serovar Typhimurium. *Mol Microbiol* **57**, 691-705 (2005).
31. J. Lopez-Garrido, E. Puerta-Fernandez, J. Casadesus, A eukaryotic-like 3' untranslated region in *Salmonella enterica* hilD mRNA. *Nucleic Acids Res* **42**, 5894-5906 (2014).
32. C. C. Hung *et al.*, *Salmonella* invasion is controlled through the secondary structure of the hilD transcript. *PLoS Pathog* **15**, e1007700 (2019).
33. D. Pérez-Morales *et al.*, An incoherent feedforward loop formed by SirA/BarA, HilE and HilD is involved in controlling the growth cost of virulence factor expression by *Salmonella* Typhimurium. *PLoS Pathog* **17**, e1009630 (2021).
34. J. R. Grenz, J. E. Cott Chubiz, P. Thaprawat, J. M. Slauch, HilE Regulates HilD by Blocking DNA Binding in *Salmonella enterica* Serovar Typhimurium. *J Bacteriol* **200** (2018).
35. I. N. Olekhovich, R. J. Kadner, DNA-binding activities of the HilC and HilD virulence regulatory proteins of *Salmonella enterica* serovar Typhimurium. *J Bacteriol* **184**, 4148-4160 (2002).
36. C. Smith, A. M. Stringer, C. Mao, M. J. Palumbo, J. T. Wade, Mapping the Regulatory Network for *Salmonella enterica* Serovar Typhimurium Invasion. *MBio* **7** (2016).
37. M. Kalafatis, J. M. Slauch, Long-Distance Effects of H-NS Binding in the Control of hilD Expression in the *Salmonella* SPI1 Locus. *J Bacteriol* **203**, e0030821 (2021).
38. M. Ackermann *et al.*, Self-destructive cooperation mediated by phenotypic noise. *Nature* **454**, 987-990 (2008).
39. M. Diard *et al.*, Stabilization of cooperative virulence by the expression of an avirulent phenotype. *Nature* **494**, 353-356 (2013).
40. I. Hautefort, M. J. Proença, J. C. Hinton, Single-copy green fluorescent protein gene fusions allow accurate measurement of *Salmonella* gene expression in vitro and during infection of mammalian cells. *Appl Environ Microbiol* **69**, 7480-7491 (2003).

41. S. Saini, J. R. Ellermeier, J. M. Slauch, C. V. Rao, The role of coupled positive feedback in the expression of the SPI1 type three secretion system in *Salmonella*. *PLoS Pathog* **6**, e1001025 (2010).
42. M. A. Sánchez-Romero, J. Casadesús, Contribution of SPI-1 bistability to *Salmonella enterica* cooperative virulence: insights from single cell analysis. *Scientific reports* **8**, 14875 (2018).
43. M. C. Schlumberger *et al.*, Real-time imaging of type III secretion: *Salmonella* SipA injection into host cells. *Proc Natl Acad Sci U S A* **102**, 12548-12553 (2005).
44. M. A. Sánchez-Romero, J. Casadesús, Single Cell Analysis of Bistable Expression of Pathogenicity Island 1 and the Flagellar Regulon in *Salmonella enterica*. *Microorganisms* **9** (2021).
45. A. Sturm *et al.*, The cost of virulence: retarded growth of *Salmonella Typhimurium* cells expressing type III secretion system 1. *PLoS Pathog* **7**, e1002143 (2011).
46. M. Arnoldini *et al.*, Bistable expression of virulence genes in *salmonella* leads to the formation of an antibiotic-tolerant subpopulation. *PLoS Biol* **12**, e1001928 (2014).
47. B. Stecher *et al.*, *Salmonella enterica* serovar typhimurium exploits inflammation to compete with the intestinal microbiota. *PLoS Biol* **5**, 2177-2189 (2007).
48. L. Bossi, A. Schwartz, B. Guillemandet, M. Boudvillain, N. Figueroa-Bossi, A role for Rho-dependent polarity in gene regulation by a noncoding small RNA. *Genes Dev* **26**, 1864-1873 (2012).
49. C. P. Lostroh, C. A. Lee, The HilA box and sequences outside it determine the magnitude of HilA-dependent activation of P(prgH) from *Salmonella* pathogenicity island 1. *J Bacteriol* **183**, 4876-4885 (2001).
50. R. A. Daly, C. P. Lostroh, Genetic analysis of the *Salmonella* transcription factor HilA. *Canadian journal of microbiology* **54**, 854-860 (2008).
51. M. G. Wulf *et al.*, Non-templated addition and template switching by Moloney murine leukemia virus (MMLV)-based reverse transcriptases co-occur and compete with each other. *J Biol Chem* **294**, 18220-18231 (2019).
52. C. Kröger *et al.*, An infection-relevant transcriptomic compendium for *Salmonella enterica* Serovar Typhimurium. *Cell Host Microbe* **14**, 683-695 (2013).
53. N. A. Lerminiaux, K. D. MacKenzie, A. D. S. Cameron, *Salmonella* Pathogenicity Island 1 (SPI-1): The Evolution and Stabilization of a Core Genomic Type Three Secretion System. *Microorganisms* **8** (2020).
54. E. Bouffartigues, M. Buckle, C. Badaut, A. Travers, S. Rimsky, H-NS cooperative binding to high-affinity sites in a regulatory element results in transcriptional silencing. *Nat Struct Mol Biol* **14**, 441-448 (2007).
55. V. H. Bustamante *et al.*, Hld-mediated transcriptional cross-talk between SPI-1 and SPI-2. *Proc Natl Acad Sci U S A* **105**, 14591-14596 (2008).
56. L. C. Martínez, M. M. Banda, M. Fernández-Mora, F. J. Santana, V. H. Bustamante, Hld induces expression of *Salmonella* pathogenicity island 2 genes by displacing the global negative regulator H-NS from ssrAB. *J Bacteriol* **196**, 3746-3755 (2014).
57. A. A. Rangarajan, K. Schnetz, Interference of transcription across H-NS binding sites and repression by H-NS. *Mol Microbiol* **108**, 226-239 (2018).
58. J. T. Wade, D. C. Grainger, Waking the neighbours: disruption of H-NS repression by overlapping transcription. *Mol Microbiol* **108**, 221-225 (2018).
59. H. Leh *et al.*, Bacterial-Chromatin Structural Proteins Regulate the Bimodal Expression of the Locus of Enterocyte Effacement (LEE) Pathogenicity Island in Enteropathogenic *Escherichia coli*. *mBio* **8** (2017).
60. J. Soudet, F. Stutz, Regulation of Gene Expression and Replication Initiation by Non-Coding Transcription: A Model Based on Reshaping Nucleosome-Depleted Regions:

Influence of Pervasive Transcription on Chromatin Structure. *Bioessays* **41**, e1900043 (2019).

61. K. Struhl, Transcriptional noise and the fidelity of initiation by RNA polymerase II. *Nat Struct Mol Biol* **14**, 103-105 (2007).
62. J. T. Wade, D. C. Grainger, Pervasive transcription: illuminating the dark matter of bacterial transcriptomes. *Nat Rev Microbiol* **12**, 647-653 (2014).
63. R. Silva-Rocha, V. de Lorenzo, Noise and robustness in prokaryotic regulatory networks. *Annu Rev Microbiol* **64**, 257-275 (2010).
64. M. Kaern, T. C. Elston, W. J. Blake, J. J. Collins, Stochasticity in gene expression: from theories to phenotypes. *Nat Rev Genet* **6**, 451-464 (2005).
65. M. A. Sanchez-Romero, J. Casadesus, Waddington's Landscapes in the Bacterial World. *Front Microbiol* **12**, 685080 (2021).
66. K. Lilleengen, Typing of *Salmonella typhimurium* by means of bacteriophage. *Acta Pathol. Microbiol. Scand.* **77**, 2-125 (1948).
67. H. Schmieger, Phage P22-mutants with increased or decreased transduction abilities. *Mol Gen Genet* **119**, 75-88 (1972).
68. K. A. Datsenko, B. L. Wanner, One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* **97**, 6640-6645 (2000).
69. S. Uzzau, N. Figueroa-Bossi, S. Rubino, L. Bossi, Epitope tagging of chromosomal genes in *Salmonella*. *Proc Natl Acad Sci U S A* **98**, 15264-15269 (2001).
70. F. Liu, K. Zheng, H. C. Chen, Z. F. Liu, Capping-RACE: a simple, accurate, and sensitive 5' RACE method for use in prokaryotes. *Nucleic Acids Res* **46**, e129 (2018).
71. V. S. Lioy, F. Boccard, Conformational Studies of Bacterial Chromosomes by High-Throughput Sequencing Methods. *Methods Enzymol* **612**, 25-45 (2018).

## Figure Legends

**Fig. 1.** NusG depletion enhances HilD-dependent SPI-1 bistability. The strains used, MA14302 (*hilD*<sup>+</sup>) and MA14561 (*hilDΔ309*), carry a *hilA-gfp<sup>SF</sup>* translational gene fusion (*hilA::gfp<sup>SF</sup>ΔK28*) and a chromosomal P<sup>Tac</sup> promoter-mCherry gene fusion in the ARA-inducible-NusG depletion background. (A) Representative image of MA14302 cells grown at 37°C to early stationary phase visualized by fluorescence microscopy under 100x magnification. (B) and (C) Representative flow cytometry analysis of cells from strains MA14302 (B) and MA14561 (C) grown as in (A). The GFP fluorescence intensity distribution was examined in strains carrying *gfp* translational fusions. The full genotypes of MA14302 and MA14561 are shown in *SI Appendix*, Table S1. For the construction of *hilA::gfp<sup>SF</sup>ΔK28* and *hilDΔ309* by λ red recombineering, DNA primers (listed in *SI Appendix*, Table S2) were used as detailed in *SI Appendix*, Table S3.

**Fig. 2.** NusG depletion induces HilD-dependent activation of *hilD* and *prgH* promoters. (A) and (B) Quantification of *hilD* mRNA (A) and *prgH* mRNA (B) from strains MA14302 (*hilD*<sup>+</sup>) and MA14561 (*hilDΔ309*) grown to early stationary phase in the absence or in the presence of 0.1% ARA. RNA was quantified by two-step reverse transcription-quantitative PCR (RT-qPCR). Ct values were normalized to the Ct values determined for *ompA* mRNA. Transcript levels are shown relative to those of untreated MA14302, set as 1. (C) Measurement of HilD protein binding to the *hilD* promoter. HilD-bound DNA was isolated by chromatin immunoprecipitation from strain MA14363 (carrying a chromosomal *hilD*-3xFLAG fusion) and quantified by real-time PCR (ChIP-qPCR). Ct values were normalized to the values of a *katE* gene reference. Results are presented as ratios between the values measured in cells grown in ARA-supplemented medium and the values from untreated cells. (D) and (E) 5' RACE-Seq analysis of *hilD* and *prgH* promoter activity, respectively. RNA from strain MA14302 was reverse-transcribed in the presence of a template-switching oligonucleotide (TSO). The resulting cDNA was used as template for semiquantitative PCR with primers carrying Illumina adapter sequences at their 5' ends. Amplified DNA was subjected to high-throughput sequencing. Read counts were normalized to those measured at the *ompA* promoter. Results shown represent the ratios between the normalized counts from ARA-treated cells and those from untreated cells. (F) and (G) Contribution of distal transcription to *hilD* and *prgH* RNA levels, respectively. RNA was reverse-transcribed with primers annealing inside the promoter-proximal portion of *hilD* or *prgH* (predicted transcripts are depicted as wavy lines). The resulting cDNAs (straight lines) were used for qPCR amplification with primers annealing close to (qPCR-1) or farther away from (qPCR-2) the RT priming site. Ct values were normalized to the Ct values determined for *ompA* mRNA. Transcript levels are shown relative to those of untreated MA14302 cells, set as 1. All the data in this figure originate from ≥3 independent experiments (with error bars indicating standard deviations). Statistical significance was determined by unpaired two-tailed Student t-tests with Welch's correction for unequal variances (\*, P ≤ 0.05; \*\*, P, ≤ 0.01; \*\*\*, P ≤ 0.001). In (F) and (G), the calculated P values for

the differences between untreated samples (green bars) were 0.0002 (*F*) and < 0.0001 (*G*). The P values for the ARA-treated samples (red bars) were 0.0108 (*F*) and 0.0025 (*G*). The oligonucleotides used as primers in the above experiments are listed in *SI Appendix*, Table S4. Further experimental details are provided in Materials and Methods.




**Fig. 3.** Overlapping transcription triggers HilD-dependent activation of *hilD* and *prgH* promoters in NusG-depleted cells. (A) Schematic diagram showing the gene organization on the 5' side of *hilD* in strains MA14358 (*hilD<sup>+</sup>*) and MA14569 (*hilDΔ309*). Both strains contain a *tetR-P<sup>tetA</sup>* cassette that replaces a 10,828 bp segment of SPI-1 and places the *P<sup>tetA</sup>* promoter 610 bp upstream of the main *hilD* TSS. (B) and (C) Quantification of *hilD* mRNA (B) and *prgH* mRNA (C) in cells grown to early stationary phase in the presence or absence of either ARA or AHTc, or in the presence of both. RNA was quantified by two-step RT-qPCR. Ct values were normalized to the Ct values determined for *ompA* mRNA. Transcript levels are shown relative to those of untreated MA14358, set as 1. (D) and (E) 5' RACE-Seq analysis of *hilD* and *prgH* promoter activity, respectively. RNA from strain MA14358 grown under the different conditions was processed as described in the legend of Fig. 2D and E. Results shown represent the ratios between the normalized read counts from treated cells and those from untreated cells. (F) Measurement of HilD protein binding to the *hilD* promoter. HilD-bound DNA was isolated by chromatin immunoprecipitation from strain MA14505 (carrying a chromosomal *hilD*-3xFLAG fusion) and quantified by real-time PCR (ChIP-qPCR). Ct values were normalized to the values of a *katE* gene reference. Results are presented as ratios between the values measured in cells grown in a medium supplemented with ARA and AHTc and those from untreated cells. All the data in this figure originate from three or more independent experiments (with error bars indicating standard deviations). Statistical significance was determined by unpaired two-tailed Student's t-tests with Welch's correction for unequal variances (ns, P > 0.05; \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.001). The oligonucleotides used as primers in the above experiments are listed in *SI Appendix*, Table S4.

**Fig. 4.** Overlapping transcription promotes HilD-dependent bistability of SPI-1 expression. Strains MA14358 (*hilD<sup>+</sup>*) and MA14569 (*hilDΔ309*), carry the *tetR-P<sup>tetA</sup>* cassette (Fig. 3A) combined with *hilA::gfp<sup>sf</sup>ΔK28* and the chromosomal *P<sup>Tac</sup>-mCherry* in the ARA-inducible-NusG depletion background. Cells grown to early stationary phase under the indicated conditions were used for single-cell analysis by flow cytometry. GFP fluorescence was measured and the distribution of *hilA<sup>OFF</sup>* and *hilA<sup>ON</sup>* cells is shown in heat maps. (A) MA14358. (B) MA14569.


**Fig. 5.** NusG depletion affects H-NS binding to specific portions of SPI-1. (A) Representative ChIP-Seq profiles from NusG-depletable strain MA13748 (*hns*-3xFLAG) grown to early stationary phase in the presence or absence of 0.1% ARA. (B) Read depth quantification in the sections framed by the dashed rectangles in (A) and in the *nrdF-proV* intergenic region. Read depth values (determined by the bedcov tool of the Samtools suite) were normalized to the values from the entire genome. The results shown represent the ratios between the

normalized values from IP samples and those from input DNA. (C) Representative ChIP-Seq profiles from NusG-depletable strain MA14513 ( $\Delta[sitA-prgH]::tetR-P^{tetA}$ ,  $hilA::gfp^S\Delta K28$ ,  $hns-3xFLAG$ ) grown to early stationary phase in the presence or absence of ARA + AHTc. (D) Read depth quantification in the intervals framed by the dashed rectangles in (C). Read depth was calculated and normalized as in (B). The data in (B) and (C) represent the means from three independent ChIP-Seq experiments (with error bars indicating standard deviations).


**Fig. 6.** Model for activation of *hilD* and *prgH* promoters by overlapping transcription. (A) A spurious transcription initiation event occurs at the edge of a patch of oligomerized H-NS (orange circles). Transcript elongation through bound H-NS is prevented by NusG-mediated recruitment of Rho factor (stop sign). (B) Occasionally, the transcript eludes Rho termination and progresses along the DNA dislodging H-NS in front of its path. This action opens a kinetic window during which RNA polymerase (green ovals) can bind to promoters that become exposed, including *hilD* secondary promoters (not shown) and the primary *hilD* promoter. (C) Activation of the *hilD* promoter leads to an increase in the levels of HilD protein (blue double-ovals), which, upon binding to the *hilD* regulatory region, further stimulates *hilD* transcription and protein production. (D) This locks the system in a positive feedback loop: accumulation of HilD leads to more *hilD* transcription and more HilD protein made. Through HilA (not shown) it also results in high-level transcription of the *prgH* gene. Divergent transcription further enhances the accessibility of additional spurious promoter sequences further contributing to runaway transcription activation.



Figueroa-Bossi *et al.*, Fig. 2




Figueroa-Bossi *et al.*, Fig. 3



Figueroa-Bossi *et al.*, Fig. 4


A

*hilD*<sup>+</sup>





B

*hilDΔ309*



Figueroa-Bossi *et al.*, Fig. 5





## **Supporting information for:**

### **Pervasive transcription enhances the accessibility of H-NS-silenced promoters and generates bistability in *Salmonella* virulence gene expression**

Nara Figueroa-Bossi<sup>a</sup>, María Antonia Sanchez-Romero<sup>b</sup>, Patricia Kerboriou<sup>a</sup>, Delphine Naquin<sup>a</sup>, Clara Mendes<sup>a</sup>, Philippe Bouloc<sup>a</sup>, Josep Casadesús<sup>c</sup> and Lionello Bossi<sup>a1</sup>

<sup>a</sup>Université Paris-Saclay, CEA, CNRS, Institut de Biologie Intégrative de la Cellule (I2BC), Gif-sur-Yvette, France, <sup>b</sup>Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain and <sup>c</sup>Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain

<sup>1</sup>To whom correspondence may be addressed. Email: lionello.bossi@i2bc.paris-saclay.fr

#### **This PDF file includes:**

Supplementary text (Materials and Methods)

SI References

Figures S1 to S6

Tables S1 to S4

## Supplementary Materials and Methods

**RT-qPCR.** Amplification reactions were set up in 384-well plates by mixing serial dilutions of each reverse-transcribed sample with the appropriate primer pairs (each primer used at a 0.25 µM final concentration) and the LightCycler 480 SYBR Green I Master Mix (Roche Applied Science). Real-time qPCR was carried out in a LightCycler 480 Instrument (Roche) with the following program: activation: 95°C for 5 min; amplification (40 cycles): 95°C for 10 sec; 55°C for 20 sec; 72°C for 20 sec; melting curve: 95°C for 30 sec; 65°C for 30 sec (ramp 0.06 °C/sec, 10 acquisitions/°C). Target-to-reference transcript ratios and relative transcript levels were calculated with the Pflafl method (1).

**Template switching Reverse Transcription.** Total RNA (1 µg) was combined with 1 µl of a mixture of up to four gene-specific primers, 5 µM each (including AI41 (*hilD*), AI48 (*prgH*) and AJ33 (*ompA*)), and 1 µl of 10 mM dNTPs in a 6 µl final volume. After a 5 min treatment at 70°C (in a Thermocycler), samples were quickly cooled on ice. Each sample were then mixed with 2.5 µl of Template Switching Buffer (4x), 0.5 µl of 75 µl of Template Switching Oligonucleotide (TSO) and 1 µl of Template Switching RT Enzyme Mix in a final volume of 10 µl. Reverse transcription was carried out for 90 min at 42°C, followed by a 5 min incubation at 85°C. The 42 nucleotide-long TSO carries three 3'-terminal riboguanosines that hybridize to the polycytosine overhang (typically 3 or 4 Cs) added by the RT enzyme when it reaches the 5' end of the RNA. This allows the RT enzyme to switch template and copy the TSO.

**CHIP-Seq analysis.** Following two washes with TBS buffer, Formaldehyde-treated cells were resuspended in 0.5 ml of Lysis buffer (50mM Tris pH 7.4, 150mM NaCl, 1mM EDTA supplemented with cOmplete™ Mini Protease Inhibitor cocktail (Sigma-Aldrich). Then, 3 µl of Ready-Lyse™ Lysozyme solution, 25,000 – 40,000 U/µl (Lucigen R1804M) were added and incubated on ice for 10 min, followed by the addition of 25 µl of 25% Triton and 450 µl of Lysis buffer. Cells were disrupted in a Covaris 220 focused ultrasonicator (Peak Incidence = 140W; Duty Factor = 5; Cycles per burst = 200). This step was followed by 10 min centrifugation at 16 000 rcf at 4°C. After removing aliquots for “Input” controls, supernatants (0.9 ml) were treated overnight with Anti-Flag M2 affinity Gel (Sigma A2220, 40 µl of slurry per sample) on a gyratory wheel at 8°C. Next day, beads were washed in the cold with 500 µl of TBS plus 0.05% Tween 20 for 10 minutes, followed by four TBS washes, of 10 minute each. The elution of 3xFLAG-H-NS DNA complex from the beads was accomplished as follows: 3xFLAG peptide solution (prepared according to Sigma Aldrich instructions) was diluted with TBS (3 µl of 3xFLAG peptide concentrated solution per 100 µl of TBS) and an aliquot of 2.5 times volume (relative to beads) of the peptide-TBS solution was added on top of the beads. Tubes were incubated for 1 hour on the gyratory wheel at 8°C. Samples were centrifuged briefly and supernatant transferred to a clean tube. Inputs as well as samples were treated with Proteinase K (2.5 µl of a 2 mg/ml solution) at 65°C

overnight. DNA was cleaned using Qiagen Mini-elute reaction clean up kit. DNA fragments were end-repaired and dA-tailed (NEB#E7595), Illumina TruSeq adapters were ligated (NEB#E6040) and libraries were amplified with Kapa Hifi polymerase (Kapa Biosystem #KK2103). Final libraries quality was assessed on an Agilent Bioanalyzer 2100, using an Agilent High Sensitivity DNA Kit. Libraries were pooled in equimolar proportions and sequenced on a Paired-End 2x75 bp run, on an Illumina NextSeq500 instrument. Output files were demultiplexed and adapters were removed. Only reads longer than 10 pb were kept for analysis. The raw data from all CHIP-Seq experiments were deposited into ArrayExpress under the accession number E-MTAB-11386.

**Measurement of  $\beta$ -galactosidase activity.** Static overnight cultures were diluted 1:200 in 2 ml of LB (with or without ARA) and grown with shaking at 37°C to early or mid-stationary phase. Bacteria were harvested from 1 ml aliquots and resuspended in 1 ml of PBS.  $\beta$ -galactosidase activity was assayed in toluene-permeabilized cells as described by Miller (2) and is expressed in Miller units. Measurements were repeated three times, each time using duplicate cultures originating from independent colonies.


**Statistics and Reproducibility.** All data described in this paper originate from three or more independent experiments, with one or more measurements performed on each replicate of the experiment. Statistical significance was calculated as specified in the legends to the figures. In pairwise comparisons of expression levels, significance was generally determined by unpaired two-tailed Student's t-tests with Welch's correction for unequal variances. In flow cytometry experiments, significance was determined performing one-way ANOVA with Dunnett's multiple comparisons test. All statistical analyses were done GraphPad Prism 9 software. P values were included in the figures (using the asterisk symbol) or specified in the figure legends.

**Bioinformatic analyses.** Demultiplexing of raw data from the Illumina sequencer was performed with the bcl2fastq2 V2.2.18.12 program and adapters were trimmed with Cutadapt1.15. The reads from the CHIP-Seq experiments were mapped on the genomes of *Salmonella enterica* serovar Typhimurium strain LT2 (wt) and the SPI-1-modified variant MA14358 with BWA 0.6.2-r126. Bedgraph files were generated from aligned Bam files using bedtools genomecov. Coverage track (number of reads per base) was converted to the BigWig format using the bedGraphToBigWig command line utility from UCSC. Read depth was calculated using the bedcov tool of the Samtools suite. Bam and Bigwig files were visualized with Integrative Genome Viewer (IGV) (3). In the processing of the RACE-Seq data, the reads containing the TSO were filtered and kept thanks to grep command in the SeqKit package. These reads were then trimmed with the PRINSEQ tool to remove 33 bp from the 5' end (the amplified portion of the TSO except the terminal 3Gs).

## References


1. M. W. Pfaffl, A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* **29**, e45 (2001).
2. J. H. Miller, *A Short Course in Bacterial Genetics. A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria*. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1992).
3. J. T. Robinson *et al.*, Integrative genomics viewer. *Nat Biotechnol* **29**, 24-26 (2011).

*SI Appendix Fig. S1*




**Fig. S1.** Upregulation of SPI genes in NusG-depleted cells is largely Hild-mediated. Strains carrying translational *lacZ* gene fusions to SPI genes in the ARA-inducible NusG depletion background were grown at 37°C in LB (with or without ARA) for 4.5 hours (strains with *invB-lacZ* and *sopB-lacZ*) or for 6 hours (strain with *sseE-lacZ*). At this time, OD<sub>600</sub> readings ranged between 1.1 and 2.1 (4.5 h) or between 1.9 and 3.3 (6 h) depending on the strain genotype and the presence or absence of ARA. Cells were assayed for β-galactosidase activity as described in Methods. Activity is expressed in Miller units. (A) Strains MA13397 (*hild*<sup>+</sup>) and MA13971 (*Δhild*::*tet*) carrying *invB-lacZ* (SPI-1). (B) Strains MA13398 (*hild*<sup>+</sup>) and MA13972 (*Δhild*::*tet*) carrying *sopB-lacZ* (SPI-5). (C) Strains MA13409 (*hild*<sup>+</sup>) and MA13973 (*Δhild*::*tet*) carrying *sseE-lacZ* (SPI-2). The results shown represent the means of three independent determinations (with error bars indicating SD) each carried out in duplicate. Significance was determined by unpaired two-tailed Student's t-tests with Welch's correction for unequal variances (\*, P ≤ 0.05; \*\*, P ≤ 0.01).

SI Appendix Fig. S2




**Fig. S2.** NusG depletion enhances Hild-dependent SPI-1 bistability. Flow cytometry analysis of strains MA14302 (*hild* wt) (A) and MA14561 (*hild*Δ309) (B). Cells were grown at 37°C in LB with or without ARA added to an OD<sub>600</sub> of ~0.8. GFP fluorescence intensity was measured, the number of cells analysed as 100,000, and the sizes of the SPI-1<sup>ON</sup> subpopulations are shown as percentages. The plot represents the results of four (A) and three (B) independent experiments. Statistical significance was determined by the unpaired two-tailed Student's t-test (ns, P > 0.05; \*\*, P ≤ 0.01).

*SI Appendix Fig. S3*




**Fig. S3.** Schematic representation of the primer combinations used for 5' RACE Seq. The positions of RT primers (AI41 and AI48) and reverse PCR primers are shown relative to representative reads generated by high-throughput sequencing (Bam files visualized with Integrative genome viewer, IGV).

SI Appendix Fig. S4



**Fig. S4.** 5' RACE-Seq analysis of *hilD* secondary promoters and the  $P^{tetA}$  promoter. RNA from strains MA14302 (A) and MA14358 (B and C) was reverse-transcribed in the presence of a template-switching oligonucleotide (TSO). The resulting cDNA was subjected to semi-quantitative PCR amplification (primers shown in SI Appendix, Fig. S3) and high-throughput sequencing. Read counts were normalized to those measured at the *ompA* promoter. The results shown represent the ratios between the normalized counts from treated and untreated cells. Results originate from three or four independent experiments (with error bars representing SD). Significance was determined by unpaired two-tailed Student's t tests with Welch's correction (ns,  $P > 0.05$ ; \*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$ ; \*\*\*,  $P \leq 0.001$ ).


SI Appendix Fig. S5




**Fig. S5.** Overlapping transcription promotes Hild-dependent bistability of SPI-1 expression. Flow cytometry analysis of strains MA14358 (*tetR-P<sup>tetA</sup> hild<sup>+</sup>*) (A) and MA14569 (*tetR-P<sup>tetA</sup> hildΔ309*) (B). Cells were grown at 37°C in plain LB or in LB supplemented with either ARA or AHTC or both. GFP fluorescence intensity was measured, the number of cells analyzed as 100,000 and the sizes of the SPI-1<sup>ON</sup> subpopulations are shown as percentages. The plot represents the results from five independent experiments. Statistical significance was determined by one-way ANOVA with Dunnett's multiple comparisons test (ns, P > 0.05; \*, P ≤ 0.05; \*\*\*, P ≤ 0.001; \*\*\*\*, P ≤ 0.0001).

SI Appendix Fig. S6

A




B




C

Strain MA14515 (*tetR-P<sup>tetA</sup>-Term<sup>hisL</sup> hilA::gfp<sup>SF</sup>*)




D

Strain MA14516 (*tetR-P<sup>tetA</sup>-Term<sup>hisLΔ6U</sup> hilA::gfp<sup>SF</sup>*)



**Fig. S6.** Rho-independent transcription terminator abolishes the effects of NusG depletion on SPI-1 bistability. (A) Sequence of the P<sup>tetA</sup>-Term<sup>hisL</sup> fusion in strains MA14515 (wt terminator) and MA14516 (Δ6U mutant), respectively. (B) Schematic diagram showing Term<sup>hisL</sup> position relative to P<sup>tetA</sup> and P<sup>hilD</sup> (secondary hilD promoters not shown). (C) and (D) Representative flow cytometry analysis of cells from strains MA14515 (C) and MA14516 (D). See legend in next page for details.

SI Appendix Fig. S6 continued



**Fig. S6 continued.** Rho-independent transcription terminator abolishes the effects of NusG depletion on SPI-1 bistability. Flow cytometry analysis of strains MA14515 (wt terminator) (E) and MA14516 ( $\Delta 6U$  mutant) (F), respectively. Cells were grown at 37°C in plain LB or in LB supplemented with either ARA or AHTc or both. GFP fluorescence intensity was measured, the number of cells analyzed as 100,000 and the sizes of the SPI-1<sup>ON</sup> subpopulations are shown as percentages. The plot represents the results from four independent experiments. Statistical significance was determined by one-way ANOVA with Dunnett's multiple comparisons test (ns, P > 0.05; \*, P ≤ 0.05; \*\*\*, P ≤ 0.001; \*\*\*\*, P ≤ 0.0001).

**Table S1**

Supplementary Table 1. <i>Salmonella enterica</i> serovar Typhimurium strains used in this work		Source or reference
Strain	Genotype	
MA3409	Δ[Gifsy-1]	
MA12603	Δ[Gifsy-1] hilD-tetR-P <sup>A</sup> tet-ccdB-cat	<a href="https://pubmed.ncbi.nlm.nih.gov/11902718/">https://pubmed.ncbi.nlm.nih.gov/11902718/</a>
MA12604	Δ[Gifsy-1] hilD-3xFLAG	this work
MA12996	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA	<a href="https://pubmed.ncbi.nlm.nih.gov/31589608/">https://pubmed.ncbi.nlm.nih.gov/31589608/</a>
MA13397	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA invB-lacZY_kan	<a href="https://pubmed.ncbi.nlm.nih.gov/31589608/">https://pubmed.ncbi.nlm.nih.gov/31589608/</a>
MA13398	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA sopB-lacZY_kan	<a href="https://pubmed.ncbi.nlm.nih.gov/31589608/">https://pubmed.ncbi.nlm.nih.gov/31589608/</a>
MA13409	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA sseE-lacZY_kan	<a href="https://pubmed.ncbi.nlm.nih.gov/31589608/">https://pubmed.ncbi.nlm.nih.gov/31589608/</a>
MA13748	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA hns-3xFLAG_FRT-kan-FRT	this work
MA13971	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA invB-lacZY_kan ΔhilD:tetRA	<a href="https://pubmed.ncbi.nlm.nih.gov/31589608/">https://pubmed.ncbi.nlm.nih.gov/31589608/</a>
MA13972	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA sopB-lacZY_kan ΔhilD:tetRA	<a href="https://pubmed.ncbi.nlm.nih.gov/31589608/">https://pubmed.ncbi.nlm.nih.gov/31589608/</a>
MA13973	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA sseE-lacZY_kan ΔhilD:tetRA	<a href="https://pubmed.ncbi.nlm.nih.gov/31589608/">https://pubmed.ncbi.nlm.nih.gov/31589608/</a>
MA14067	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA hilAΔK28::FRT-kan-FRT	this work
MA14082	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA hilA::gfpSF ΔK28_kan	this work
MA14115	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA ΔhilA338::gfpSF	this work
MA14122	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA ΔinvB1::gfpSF	this work
MA14271	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry_FRT-kan-FRT	this work
MA14275	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry_FRT	this work
MA14302	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry hilA::gfpSF ΔK28_kan	this work
MA14315	Δ[Gifsy-1] Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry hilA::gfpSF ΔK28_kan	this work
MA14332	Δ[Gifsy-1] Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry Δ[sitA-orgA]:tetR-P <sup>A</sup> tet-ccdB-cat hilA::gfpSF ΔK28_kan	this work
MA14339	Δ[Gifsy-1] Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry Δ[sitA-prghH332]:tetR-P <sup>A</sup> tet hilA::gfpSF ΔK28_kan	this work
MA14345	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA orgB::tetR-P <sup>A</sup> tet-ccdB-kn	this work
MA14358	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry Δ[sitA-prghH332]:tetR-P <sup>A</sup> tet hilA::gfpSF ΔK28_kan	this work
MA14363	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA hilD-3xFLAG	this work
MA14505	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry Δ[sitA-prghH332]:tetR-P <sup>A</sup> tet hilD-3xFLAG hilA::gfpSF ΔK28_kan	this work
MA14513	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA Δ[sitA-prghH332]:tetR-P <sup>A</sup> tet hilA::gfpSF ΔK28_kan hns-3xFLAG_FRT	this work
MA14515	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry Δ[sitA-prghH332]:tetR-P <sup>A</sup> tet-Term <sup>A</sup> hikL hilA::gfpSF ΔK28_kan	this work
MA14516	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry Δ[sitA-prghH332]:tetR-P <sup>A</sup> tet-Term <sup>A</sup> hikLΔ6U hilA::gfpSF ΔK28_kan	this work
MA14558	Δ[Gifsy-1] Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry hilA::gfpSF ΔK28 hilDΔ309::tetR-P <sup>A</sup> tet-ccdB-cat	this work
MA14560	Δ[Gifsy-1] Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry hilDΔ309 hilA::gfpSF ΔK28_kan	this work
MA14561	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry hilDΔ309 hilA::gfpSF ΔK28_kan	this work
MA14569	Δ[Gifsy-1] Δ[Gifsy-2] Δ[araBAD]:gtgR-P <sup>A</sup> G2R-nusG-cat Δ[nusG]:aadA Δ[hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry Δ[sitA-prghH332]:tetR-P <sup>A</sup> tet hilDΔ309 hilA::gfpSF ΔK28_kan	this work

**Table S2**

**Supplementary Table 2. DNA oligonucleotides used in this work**

Name	Sequence	Use
ppY88	GTGACTGACAATTCTACATAATAATGCCAATGAAAAAGCGCTTGACAATTATCATGGCTCG	PCR forward primer in λ-red construction (reverse primer is AA30)
ppZ13	TTTAAACATCGCCATGCATTCAAAAATGGCACCATAAACCTTCACATTAAAGCAGACATCAAAATGGCTTGACATTAAATGGCCACCATAAACCTTCACATT	PCR forward primer in λ-red construction
ppZ14	TTTAAATAAAATCTTACTTAAGTGCAGACATACAAAAATGTTAATCGCTGCTATCTTGTAGTC	PCR reverse primer in λ-red construction
ppZ45	TTTAAACATCGCCATGCATTCAAAAATGGCACCATAAACCTTCACATTAAAGCAGACATCAAAATGGCCACCATAAACCTTCACATT	PCR forward primer in λ-red construction
ppZ46	TTAATAAAAATCTTACTTAAGTGCAGACATACAAAAATGTTAATCGCTGCTATCTTGTAGTC	PCR reverse primer in λ-red construction
ppW78	GAAGAACAAAGGTAAGCAACTTGGAAAGATTCTTGATCAAGGAAAGACTACAAGAACCATGACCG	PCR forward primer in λ-red construction
ppW79	AGCCGGGGAGTTAACCTTAAAGCATTCCAGGAAGATAATTATTCATATGAAATATCTTCTCTTAG	PCR reverse primer in λ-red construction
AA30	CGTAGCTATAAGCCAAGGCTTGTAGCTTGGCGGATGGTAGGCTGGAGCTGCTT	PCR reverse primer in λ-red construction
AE12	GCAAAGGCTATATTGATGATTAATTAACACATTGGCGAGTTAAGACCCACTTCACATTA	PCR forward primer in λ-red construction (reverse primer is AH30)
AE45	GTCATCAGCGTCTGGCAGATACTTACAGAAATAACTTAAAGCTTACATTAA	PCR forward primer in λ-red construction
AE46	CATTGAATGAAGTAGGACCTGGCTATCAACACCATTAATTCAGTCTTAAAGCAGCTTCA	PCR reverse primer in λ-red construction
AF19	GATAGCGCTATCCAGGCTTGGCTCTTCTTCCGCTCTTAAAGCAGCTTCA	PCR forward primer in λ-red construction (reverse primer is AG26)
AF26	CCGATGCCAAGCAAAAGTTAAATCACATCGGAGGGCAGCTGAGCTGCTT	PCR reverse primer in λ-red construction (forward primer is AF93)
AF93	GTACGGACAGGGTATCGGTTAAATGCTGGCTGAGTGGTGCATCGGCTGAGTT	PCR forward primer in λ-red construction
AG21	TACCGACAGGGTATCGGTTAAATGCTGGCTGAGTGGTGCCTTAAGGTGAAGAACAGTTC	PCR forward primer in λ-red construction (reverse primer is AG39)
AG26	CTCTATTGAAAGATTAGAACAGCAGGGCATCAAGGGGAGTCATTGGCATGTC	PCR reverse primer in λ-red construction
AG39	CTGCTATGAAAGGAGATGCTTCAATGATGAGTGTAGGTTGCTGAGCTGCTTC	PCR reverse primer in λ-red construction
AG46	GTATAAAAACAATATAAGGCTTAAATTAGGAAAGATCTATGCTTAAAGGTGAAGAAGCTG	PCR forward primer in λ-red construction (reverse primer is AG49)
AG49	GCCAGATATTGCAAAACGAGGTTTTCATCTTACAGCAGCTGAGCTGCTTC	PCR reverse primer in λ-red construction
AH30	GGCGCAAAATGAGTTAACTTCGGCCATGGGGCTTAAAGAACGGTCAATTGGCATGTC	PCR reverse primer in λ-red construction
AH38	CATTGATAGAGTTATTTCACCTCCATCAGTGATAGAGAAAGTGAAGCAATTAC	PCR forward primer in λ-red construction
AH39	CGGTGCAATTAATACGCCAATACAGGCGTGTGATTGCTTACACTTTC	PCR reverse primer in λ-red construction
AI27	CATTGATAGAGTTATTTCACCTCCATCAGTGATAGAGAAAGTGAAGCCCCGGAAGATCATCTCCG	PCR forward primer in λ-red construction
AI28	CGGTGCAATTAATACGCCAATACAGGCGTGTGATTGCTTACACTTTC	PCR reverse primer in λ-red construction
AI39	GCTAATCATTGCAAGCAGTGTACAGCAGATCATGrGrG	Template-switching oligo (TSO)
AI41	CAACATCCCAGGTTGTCAC	RT primer (h1D)
AI48	ACCGACCTGTATTGGCTAT	RT primer (prgH)
AI50	CGCATCGTATCCACCTGG	qPCR forward primer (prgH)
AI51	GACAGGGCGAACACTTCTTG	qPCR reverse primer (prgH)
AI57	GTGTGTTGCAATGGTCTGA	qPCR reverse primer (h1D CHIP, forward primer is AL12)
AI62	TGCCGAGATACTTACAGAA	qPCR forward primer (h1D)
AI63	GTCAGTTAACCGCTCGAAA	qPCR reverse primer (h1D)
AJ32	CGTTGGAGATATTGCGGT	qPCR forward primer (ompA)
AJ33	ACCAGTCGTAGCCATTTC	RT primer (ompA)
AJ37	GAGACCAGCCCAGTTAGCA	qPCR reverse primer (ompA)
AJ38	AATGATACGGCAGCACCAGAGATCTACACTCTTCCCTACAGCAGCTTCCGATCTTAAAGCAGTGGTACAC	Illumina sequencing universal forward primer (anneals to TSO complemen
AJ39	CAAGCAGAAAGCAGCATAAGGAAAGGAATGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGCAAGTTTACCGCTCCGAAA	Illumina sequencing reverse primer (h1D primary promoter)
AJ40	CAAGCAGAAAGCAGCATAAGGAAAGGAATGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGTGCTCTGCGGTAATCT	Illumina sequencing reverse primer (h1D P3 promoter)
AJ41	CAAGCAGAAAGCAGCATAAGGAAAGGAATGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTACTCCCTGATATACCTCCG	Illumina sequencing reverse primer (h1D P4 promoter and P <sup>tet</sup> promoter)
AK19	GAGCTTCTGGCAGCTA	qPCR forward primer (katN CHIP)
AK20	CTCTGGCAAGTTAGAACAGC	qPCR reverse primer (katN CHIP)
AK53	CAAGCAGAAAGCAGCATAAGGAAAGTAAGTGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGCAAGTTTACCGCTCCGAAA	Illumina sequencing reverse primer (h1D primary promoter)
AK54	CAAGCAGAAAGCAGCATAAGGAAAGTAAGTGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGTGCTCTGCGGTAATCT	Illumina sequencing reverse primer (h1D P3 promoter)
AK55	CAAGCAGAAAGCAGCATAAGGAAAGTAAGTGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTACTCCCTGATATACCTCCG	Illumina sequencing reverse primer (h1D P4 promoter and P <sup>tet</sup> promoter)
AK93	CAAGCAGAAAGCAGCATAAGGAAAGGAATGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGATTGTTACACAAAGAACCCA	Illumina sequencing reverse primer (h1D P2 and P3 promoters)
AK94	CAAGCAGAAAGCAGCATAAGGAAAGTAAGTGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGATTGTTACACAAAGAACCCA	Illumina sequencing reverse primer (h1D P2 and P3 promoters)
AL01	CAAGCAGAAAGCAGCATAAGGAAAGGAATGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGAGACCGCCAGTTAGCA	Illumina sequencing reverse primer (ompA promoter)
AL02	CAAGCAGAAAGCAGCATAAGGAAAGTAAGTGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGAGACCGCCAGTTAGCA	Illumina sequencing reverse primer (ompA promoter)
AL06	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGCAAGTTTACCGCTCCGAAA	Illumina sequencing reverse primer (h1D primary promoter)
AL07	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGCAAGTTTACCGCTCCGAAA	Illumina sequencing reverse primer (h1D primary promoter)
AL08	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTACTCCCTGATATACCTCCG	Illumina sequencing reverse primer (h1D P4 promoter and P <sup>tet</sup> promoter)
AL09	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTACTCCCTGATATACCTCCG	Illumina sequencing reverse primer (h1D P4 promoter and P <sup>tet</sup> promoter)
AL13	CAAGCAGAAAGCAGCATAAGGAAAGGAATGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGCATCGTATCCACCTGG	Illumina sequencing reverse primer (prgH promoter)
AL14	CAAGCAGAAAGCAGCATAAGGAAAGTAAGTGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGCATCGTATCCACCTGG	Illumina sequencing reverse primer (prgH promoter)
AL15	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGCATCGTATCCACCTGG	Illumina sequencing reverse primer (prgH promoter)
AL16	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGCATCGTATCCACCTGG	Illumina sequencing reverse primer (prgH promoter)
AL17	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGAGACCGCCAGTTAGCA	Illumina sequencing reverse primer (ompA promoter)
AL18	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGAGACCGCCAGTTAGCA	Illumina sequencing reverse primer (ompA promoter)
AL21	TTAGTACTAACGGTCAGGTTAG	RT primer (h1A)
AM24	CAAGCAGAAAGCAGCATAAGGAAAGGAATGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTCGGGCTCGGGTTTATATGTT	Illumina sequencing reverse primer (h1A promoter)
AM25	CAAGCAGAAAGCAGCATAAGGAAAGTAAGTGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTCGGGCTCGGGTTTATATGTT	Illumina sequencing reverse primer (h1A promoter)
AM26	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTCGGGCTCGGGTTTATATGTT	Illumina sequencing reverse primer (h1A promoter)
AM27	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTCGGGCTCGGGTTTATATGTT	Illumina sequencing reverse primer (h1A promoter)
AL85	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGTTGCTCTGCGGTAATCT	Illumina sequencing reverse primer (h1D P3 promoter)
AL86	CAAGCAGAAAGCAGCATAAGGAAAGTCGTCGTGACTGGAGTTCAAGCAGCTGCTCTTCCGATCTGTTGCTCTGCGGTAATCT	Illumina sequencing reverse primer (h1D P3 promoter)
AM38	TATAACCTTCCGCCGTAC	qPCR forward primer (prgH antisense)
AM39	CAGACCGCTAATTGTCG	qPCR reverse primer (prgH antisense)

Red lettering denotes sequences annealing to chromosomal DNA or cDNA in λ red recombineering experiments and in 5'RACE-Seq analysis, respectively. Colored hexameric sequences correspond to indexes used in Illumina sequencing.

### Table S3

**Supplementary Table 3. Relevant alleles constructed by  $\lambda$  red recombineering**

Allele	Primer pair	template	Notes
hilD-tetR-P <sup>A</sup> tet-ccdB-cat	ppZ13 - ppZ14	pNNB5	AHTc-inducible ccdB on the 3' side of hilD. Step 1 in the construction of markerless hilD-3xFLAG
hilD-3xFLAG	ppZ45 - ppZ46	pSUB11	
hns-3xFLAG_FRT-kan-FRT	ppW78- ppW79	pSUB11	
$\Delta$ hilD::tetRA	AE45 - AE46	pTn5-tetRA-SH1	
hilA $\Delta$ K28::FRT-kan-FRT	AF93 - AF26	pKD13	FRT-kan-FRT insertion removing a 28266 bp SPI-1 segment from position 338 of hilA to the end of STM2906. Step 1 in the construction of hilA::gfpSF $\Delta$ K28_ kan
$\Delta$ hilA338:gfpSF	AG21 - AG39	pNCM2	
$\Delta$ invB1:gfpSF	AG46 - AG49	pNCM2	
$\Delta$ [hisGDCBHAFIE]:P <sup>A</sup> Tac-mCherry_FRT-kan-FRT	ppY88 - AA30	pNCM4	
$\Delta$ [sitA-orgA]:tetR-P <sup>A</sup> tet-ccdB-cat	AE12 - AH30	pNNB5	Step 1 in the construction of $\Delta$ [sitA-prgH332]:tetR-P <sup>A</sup> tet
$\Delta$ [sitA-prgH332]:tetR-P <sup>A</sup> tet	AH38 - AH39	Fill-in	Primers anneal to each other
$\Delta$ [sitA-prgH332]:tetR-P <sup>A</sup> tet-Term <sup>A</sup> hisL	AI27 - AI28	Fill-in	Primers anneal to each other
orgB::tetR-P <sup>A</sup> tet-ccdB-kan	AF19 - AG26	pNNB7	Step 1 for moving hilD-3xFLAG in the NusG depletable background
hilD $\Delta$ 309::tetR-P <sup>A</sup> tet-ccdB-cat	AL78 - AL79	pNNB5	Step 1 in the construction of markerless hilD309
hilD $\Delta$ 309	AL81 - AL82	Fill-in	Primers anneal to each other

## Table S4

**Supplementary Table 4. Primers used in qPCR experiments**

Fig. 2a	gene of interest	hild	RT primer	qPCR primer pair
	reference gene	ompA	AJ41	AI62 - AI63
Fig. 2b	gene of interest	prgH	RT primer	qPCR primer pair
	reference gene	ompA	AJ33	AI50 - AI51
Fig. 2c	gene of interest	prgH-hild IG	qPCR primer pair	
	reference gene	katN	AL12 - AI57	
Fig. 2f	gene of interest	hild	RT primer	qPCR-1 primer pair
	reference gene	ompA	AJ41	AI62 - AI63
	gene of interest	prgH antisense	AJ33	AJ32 - AJ37
	reference gene	ompA	AM38 - AM39	qPCR-2 primer pair
Fig. 2g	gene of interest	prgH	RT primer	AM32 - AM37
	reference gene	ompA	AJ48	AJ32 - AJ37
	gene of interest	hild antisense	AJ33	qPCR-1 primer pair
	reference gene	ompA	AI62 - AI63	AJ32 - AJ37
Fig. 3b	gene of interest	hild	RT primer	qPCR primer pair
	reference gene	ompA	AJ41	AI62 - AI63
Fig. 3c	gene of interest	prgH	AJ33	AJ32 - AJ37
	reference gene	ompA	AI48	AI50 - AI51
Fig. 3f	gene of interest	prgH-hild IG	qPCR primer pair	
	reference gene	katN	AL12 - AI57	
			AK19 - AK20	